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TriglyceridesHIV-associated sensory neuropathy (HIV-SN) is a frequent complication of HIV infection and a major
source of morbidity. A cross-sectional deep proﬁling study examining HIV-SN was conducted in people
living with HIV in a high resource setting using a battery of measures which included the following:
parameters of pain and sensory symptoms (7 day pain diary, Neuropathic Pain Symptom Inventory [NPSI]
and Brief Pain Inventory [BPI]), sensory innervation (structured neurological examination, quantitative
sensory testing [QST] and intraepidermal nerve ﬁbre density [IENFD]), psychological state (Pain Anxiety
Symptoms Scale-20 [PASS-20], Depression Anxiety and Positive Outlook Scale [DAPOS], and Pain Catas-
trophizing Scale [PCS], insomnia (Insomnia Severity Index [ISI]), and quality of life (Short Form (36)
Health Survey [SF-36]). The diagnostic utility of the Brief Peripheral Neuropathy Screen (BPNS), Utah
Early Neuropathy Scale (UENS), and Toronto Clinical Scoring System (TCSS) were evaluated. Thirty-six
healthy volunteers and 66 HIV infected participants were recruited. A novel triumvirate case deﬁnition
for HIV-SN was used that required 2 out of 3 of the following: 2 or more abnormal QST ﬁndings, reduced
IENFD, and signs of a peripheral neuropathy on a structured neurological examination. Of those with HIV,
42% fulﬁlled the case deﬁnition for HIV-SN (n = 28), of whom 75% (n = 21) reported pain. The most fre-
quent QST abnormalities in HIV-SN were loss of function in mechanical and vibration detection. Struc-
tured clinical examination was superior to QST or IENFD in HIV-SN diagnosis. HIV-SN participants had
higher plasma triglyceride, concentrations depression, anxiety and catastrophizing scores, and preva-
lence of insomnia than HIV participants without HIV-SN.
 2014 The Authors. Published by Elsevier B.V. on behalf of International Association for the Study of
Pain. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).The current global prevalence of HIV is about 34 million [29].
HIV-associated sensory polyneuropathy (HIV-SN) is a distal sym-
metrical, predominantly sensory, polyneuropathy characterised
by a ‘‘dying back’’ pattern of axonal degeneration. It is a frequentand often painful complication of HIV infection, and its treatment
[31,12,13] with both viral–immune interactions and toxicity of
the nucleoside reverse transcriptase inhibitor (NRTI) class of anti-
retroviral drugs (eg, stavudine [D4T]) potentially contributes to
its pathogenesis [28,30,39,68,69]. The introduction of combination
antiretroviral treatment (cART) in the mid-1990s transformed HIV
infection from a high-mortality condition into a chronic disease,
with the life expectancy of newly diagnosed individuals now
approaching that of the general population [64,45]. Notwithstanding
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experienced by people living with HIV in both high-resource and
low-resource settings. Consequently, elucidating the nature of
and developing strategies for the prevention and management of
HIV-SN has become increasingly important.
HIV-SN affects between 27% and 57% of ambulatory HIV-
infected individuals; of those with HIV-SN, 38% to 90% experience
pain [4,22,31,40,49,62]. Neuropathic pain associated with HIV-SN
is often debilitating, adversely affecting quality of life [32]; it is also
clinically difﬁcult to treat [50]. Consequently, painful HIV-SN rep-
resents one of the largest causes of pain morbidity worldwide.
Established risk factors associated with the development of
HIV-SN include advancing age, height, and exposure to the neuro-
toxic dNRTI (nucleoside reverse transcriptase inhibitor) class of
antiretroviral agents [30,31]. The dNRTI drugs are zalcitabine
(ddC), stavudine (d4T), and didanosine (ddI). Crucially, despite
the phasing out of neurotoxic dNRTI drugs, especially in well-
resourced countries, the prevalence of HIV-SN has consistently
remained at around 40%, even in people who have no history of
exposure to dNRTIs, suggesting that drug-induced neurotoxicity
may not be a major aetiological factor for HIV-SN in the cART era
[12,22,62]. More recent cART-era population and gene association
studies have identiﬁed additional patient-related risk factors such
as ethnicity and elevated plasma triglycerides [4], as well as the
association of genes involved in the peripheral inﬂammatory
response and those affecting mitochondrial function [31]. Although
there have been several epidemiological studies documenting the
prevalence and risk factors for HIV-SN in the current cART era
[12,22,62], proﬁling studies directed at describing in detail the
HIV-SN phenotype are lacking. Speciﬁcally, factors which are cru-
cial to understanding the nature of HIV-SN, such as the relation-
ships between sensory nerve dysfunction, symptomatology,
clinical signs, patient quality of life, psychological comorbidity,
and sleep disturbance, are required. Although some early studies
did describe aspects of sensory dysfunction in the type of patients
appropriate to that era (ie, severely immunosuppressed patients,
usually with AIDS), to our knowledge, there have been no studies
detailing the HIV-SN sensory proﬁle in the cART era, where the dis-
ease has a very different clinical presentation and natural history
[8,41].
We therefore conducted a detailed deep-proﬁle study of a
cohort of HIV-infected patients with and without HIV-SN, using a
battery of techniques directed at understanding the nature and
pattern of sensory nerve dysfunction in HIV-SN and its relationship
to symptomatology, psychological morbidity, and circadian
rhythm disruption.
2. Material and methods
2.1. Study design and patients
The Pain in Neuropathy Study—HIV (PINS-HIV) was an observa-
tional single cohort cross-sectional study conducted at Chelsea and
Westminster Hospital in London. The study protocol was assessed
and approved by a local ethics committee (Riverside Research Eth-
ics Committee; NRES 09/H0706/24). Subjects participated in the
study after giving written informed consent.
Participants were recruited between July 7, 2009, and January
25, 2011, from ambulatory HIV-infected patients attending the St
Stephen’s Centre, Chelsea and Westminster Hospital. In order to
reﬂect the population treated at one of Europe’s major HIV centres,
the inclusion criteria were as inclusive as possible. Eligible persons
were all HIV-infected adults (P18 years of age), irrespective of
concurrent or previous antiretroviral (ARV) therapy, or the pres-
ence of symptoms of a peripheral neuropathy. Exclusion criteriaincluded pregnancy, coincident major psychiatric disorders
(DSM-IV), poor or no English language skills, andP4 of 10 numer-
ical rating scale (NRS) pain at recruitment from a cause other than
a peripheral neuropathy (to prevent potential confounding inﬂu-
ence on pain as well as psychological and quality-of-life patient-
reported outcomes), patients with documented central nervous
system lesions, or subjects with insufﬁcient mental capacity for
obtaining informed consent or to complete questionnaires. Skin
biopsies were not conducted on anticoagulated participants or
those who had other contraindication to skin biopsy.
The study design consisted of a single clinical assessment
appointment, at the end of which participants were given a ques-
tionnaire pack to complete and return to the study centre by mail.
During the clinical assessment appointment, participants had
detailed medical and drug histories taken by a study investigator,
who recorded the following: gender, age, ethnicity, medical his-
tory, date of HIV diagnosis, presence of a family history of neurop-
athy, presence of other potential causes of neuropathy
(hypothyroidism, diabetes, alcohol abuse, vitamin B12 deﬁciency,
and isoniazid and chemotherapy drug exposure); smoking and
alcohol consumption were assessed using UK Department of
Health methodology [27].
Basic clinical parameters were then measured for each partici-
pant (weight, height, and lying/standing blood pressures). Partici-
pants then underwent a structured neurological examination
(SNE), a detailed quantitative sensory testing (QST) assessment,
and skin biopsy, as described below. Each participant had 30 mL
of blood drawn and stored for future genotype studies.
After the clinical assessment, the study investigator collected
further drug, laboratory, and clinical investigation data from the
clinical records, where available, including detailed ARV drug his-
tories; nerve conduction study data; and the most recent routine
haematological and biochemical parameters, including HIV virus
load, CD4+ counts, plasma electrolytes, liver function enzymes,
vitamin B12, thyroid function, blood glucose, plasma lipid proﬁles,
and hepatitis B, hepatitis C, and syphilis serology (Supplementary
Document 1).
2.2. Quantitative sensory testing (QST)
Sensory proﬁles were measured using the German Research
Network on Neuropathic Pain (DFNS) QST protocol. Measurements
were performed bilaterally in the S1 dermatome (dorsum of the
feet). The DFNS has developed and validated a comprehensive
QST battery which uses standardised equipment, paradigms, and
verbal instructions as described [57,58]. This method has been
used in multiple investigations of different neuropathic pain condi-
tions to phenotypically characterise patterns of sensory nerve dys-
function [25,33,38].
The DFNS QST protocol assesses the functional characteristics of
both small and large afferent ﬁbres by recording responses to 13
thermal and mechanical stimuli. These are described elsewhere
in detail [57,58]. In brief, the DFNS QST battery tests the following
modalities in the order: cold detection threshold (CDT), warm
detection threshold (WDT), thermal sensory limen (TSL), the pres-
ence of paradoxical heat sensations (PHS), cold pain threshold
(CPT), heat pain threshold (HPT), mechanical detection threshold
(MDT), mechanical pain threshold (MPT), a stimulus response
function for pinprick sensitivity (mechanical pain sensitivity
[MPS]), allodynia (dynamic mechanical allodynia [DMA]), wind-
up ratio (WUR), vibration detection threshold (VDT), and blunt
pressure pain threshold (PPT).
The investigators (TP and MB) underwent a formal course of
instruction in conducting the DFNS QST protocol at Mannheim
University and BG University hospital, Bochum, respectively, using
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quality control purposes, each investigator was required to pro-
duce QST data sets for 18 healthy volunteer controls which were
age and sex matched to DFNS requirements to ensure an equal
number of male and female participants. Inclusion and exclusion
criteria are detailed in Supplementary Document 2.
The healthy volunteer control data were subsequently analysed
and critiqued by the DFNS to provide quality assurances for the
study centre and QST investigators. Additionally, normative data
for suprathreshold heat testing were collected from each healthy
control subject after the completion of the DFNS QST protocol
(Supplementary Document 2).
QST equipment. DFNS speciﬁcation compliant QST equipment
was used in the study as described in Supplementary Document 2.
QST data analysis. QST data entry was into an Excel-based (Excel
2007; Microsoft) data analysis system (Equista) provided by the
DFNS. This system allowed entry of basic patient demographics
and QST data. Equista performed z-score transformations of raw
QST data values by comparing against normative reference data
published by the DFNS (n = 180 subjects, bilateral assessment of
560 test areas) [37]. The DFNS normative reference data include
age, sex, and anatomical test site matched. The mathematical
transformation of QST data to z-scores has been described else-
where in detail [57].
We utilized the DFNS coding system [38] to examine combina-
tions of sensory dysfunction in HIV-SN. Accordingly, a value for a
QST parameter within the normal DFNS reference range was desig-
nated 0; the presence of thermal hypoesthesia (ie, loss of WDT or
CDT) was designated as L1; and the presence of hypoesthesia to
mechanical modalities (ie, loss of MDT or VDT) was designated
L2. Gain of sensory function to thermal modalities was designated
G1 and gain of sensory function to mechanical modalities as G2.
When both thermal and mechanical abnormalities were present,
they were designated as L3 and G3, respectively.
2.3. Heat suprathreshold nociceptive testing
We included a stimulus response function for suprathreshold
thermal stimuli. After completion of the DFNS QST protocol, partic-
ipants were exposed to 14 suprathreshold heat stimuli in a tem-
perature range of 44C to 52C at 2C intervals (Supplementary
Document 2).
As with the DFNS QST protocol, suprathreshold thermal stimuli
were generated using an MSA100 thermal stimulator (Somedic
AB), which uses a ﬂuid-cooled Peltier element thermode measur-
ing 25  50 mm.
2.4. Structured neurological examination
A comprehensive structured upper and lower limb neurological
examination was devised to detect clinical signs of a peripheral
neuropathy. The examination was performed on each patient and
included assessment of light touch and pinprick sensation, joint
position proprioception, vibration perception, deep-tendon
reﬂexes, muscle wasting, and motor power (Supplementary Docu-
ment 3). An abnormal result was taken as 2 or more symmetrical
signs in the hands or feet consistent with a peripheral neuropathy.
Sympathetic nervous system function was examined by testing
for the presence of orthostatic hypotension, as assessed by measur-
ing lying and standing blood pressure in accordance with estab-
lished protocols [16]. Lying and standing blood pressures were
each measured in triplicate using a noninvasive blood pressure
measuring system (Patient Transport Monitor HP M1275A, Hew-
lett-Packard). Lying blood pressures were measured ﬁrst, after
which the subject was asked to stand for 3 min so standing blood
pressure could be measured. Orthostatic hypotension wasdetermined to be present in subjects in whom either at least a
20 mm Hg reduction in systolic or a 10 mm Hg reduction in dia-
stolic blood pressure was observed.
2.5. Intraepidermal nerve ﬁbre density testing
The determination of IENFD in skin biopsy samples is a vali-
dated and sensitive diagnostic tool for the assessment of small
ﬁbre neuropathies, including HIV-SN [26,35,36,54,55].
Punch biopsies of skin were performed immediately after the
completion of QST. Biopsy samples were taken in accordance with
the consensus document produced by the European Federation of
Neurological Societies/Peripheral Nerve Society Guideline [35,36]
on the utilisation of skin biopsy samples in the diagnosis of periph-
eral neuropathies. After local inﬁltration of skin with 1% lidocaine
and under sterile conditions, skin biopsies were performed from a
site 10 cm proximal to the lateral malleolus with a disposable
3 mmpunch biopsy circular blade (Stiefel Laboratories Inc, GSK Plc).
The freshly collected biopsy samples were ﬁxed for 12 to 24 h in
2% paraformaldehyde/lysine/periodate ﬁxative at 4C and rinsed
with 0.08% Sorensen phosphate buffer. Samples underwent cryo-
protection with 15% and then 30% sucrose solutions for 24 h each
and were then embedded in OCT (Fisher Scientiﬁc UK Ltd), snap-
frozen by submersion in liquid nitrogen, and stored at 20C. Each
biopsy was cut into 50 lm sections with a sliding microtome.
Immunohistochemistry for PGP 9.5 (Ultraclone Ltd; dilution
1:15,000) was performed on sections using the immunoperoxidase
method. Sections from each patient were processed in 2 separate
staining runs to eliminate the risk of tissue loss and to ensure
staining quality. All sections were allocated an individual code,
and 3 sections per subject were selected randomly to undergo IEN-
FD analysis using random sequences generated by an online tool
(http://www.random.org/).
IENFD was assessed using a double bright-ﬁeld microscope at
40 magniﬁcation using established counting rules [35,36]. The
2 IENFD assessors (MB and JR) underwent instruction and technical
validation in IENFD assessment at a clinical diagnostic laboratory
overseen by one of the authors (IB). The study biopsy samples were
coded so that the assessors were unaware of the participant’s neu-
ropathy status. For the study materials, each assessor indepen-
dently determined IENFD values on 3 biopsy sections for each
participant; the resulting mean value was used. Interobserver
Pearson’s product-moment correlation coefﬁcients were deter-
mined for all the samples between the 2 microscopists; in addition,
intraobserver reliability scores were also determined for 20 of
these study sample selected randomly (http://www.random.org/).
In accordance with previously published data, IENFD values
below7.63 ﬁbre/mmwere considered to be abnormal [3]. This value
has been shown to be associated with a speciﬁcity of 90% and sensi-
tivity of 82.8% for the diagnosis of small ﬁbre neuropathies [20].
2.6. Neuropathy screening tools
Brief Peripheral Neuropathy Screen (BPNS). The BPNS tool was
developed for use by nonspecialist medical personnel to detect
HIV-SN and has been used in several studies [14,21,60]. The BPNS
consists of a set of questions relating to patient-reported symp-
toms of a peripheral neuropathy and a brief examination of the dis-
tal lower limb vibration perception and deep tendon reﬂexes.
The subjective component of the BPNS asks patients to report
the presence of pain, aching, burning in the feet and/or legs and
to report the presence of ‘pins and needles’ and numbness in feet
and/or legs. Symptom severity is scored on an 11-point scale, with
0 = absent and 10 = severe.
The lower limb examination consists of vibration perception
evaluation using a 128 Hz tuning fork maximally struck and placed
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time for a patient to lose vibration perception is graded as follows:
grade 0, >10 s; grade 1, felt for 6 to 10 s; grade 2, felt for 5 s or less;
and grade 3, no perception of vibration. Ankle reﬂexes were
assessed relative to knee reﬂexes and graded as follows: grade 0,
absent; grade 1, hypoactive; grade 2, normal; grade 4, clonus.
As originally described, the BPNS is not proscriptive on the def-
inition of peripheral neuropathy used, and several studies have
used different deﬁnitions for diagnosing HIV-SN. We used the
method described by Cherry et al. [14], which has also been used
in a number of recent studies [1,10,11,72] and which requires both
symptoms and signs. Subjects are considered to have HIV-SN if
they have at least 1 symptom and either reduced or absent vibra-
tion sensation or ankle reﬂexes.
Toronto Clinical Scoring System (TCSS). The TCSS was developed
as a screening tool for diabetic peripheral neuropathy [48]. Subse-
quent studies validated its utility in reﬂecting diabetic neuropathy
severity, its correlation with clinical electrophysiological measures,
and microscopic morphological changes in peripheral nerve biopsy
samples [9]. The TCSS uses a simpliﬁed neurological examination
assessing peripheral sensory perception, deep tendon reﬂexes,
and the presence of neuropathy symptoms.
Sensory testing is performed on the ﬁrst toe for the following:
pinprick sensation using a Neurotip pin (Owen Mumford); temper-
ature discrimination (warm- and cool-water-ﬁlled test tubes);
light touch with a 10 g monoﬁlament; and vibration with a maxi-
mally struck 128 Hz tuning fork, performed at the ﬁrst toe.
Responses were rated as normal or abnormal and were assigned
0 or 1 point, respectively. Scores range from 0 to a maximum of 19.
Deep tendon reﬂexes scores are graded for each side as loss, 2;
reduced, 1; and normal, 0. The presence of each following neurop-
athy symptom scores 1 point: pain, numbness, tingling and weak-
ness in the feet; the presence of similar upper limb symptoms; and
the presence of unsteadiness on ambulation.
Utah Early Neuropathy Scale (UENS). The UENS is a physical
examination scale developed speciﬁcally for the detection of early
sensory-predominant diabetic polyneuropathy [61]. The emphasis
of UENS is on the severity and spatial distribution of pin-evoked
sharp sensation loss in the lower limb. The scale was developed
and validated in a population with early diabetic peripheral
neuropathy.
The UENS assesses sharp sensation in the lower leg relative to
an unaffected portion of skin. A Neurotip pin is applied to the dor-
sum of the ﬁrst toe and, working centripetally in 2 cm increments,
the subject is asked at each application if they feel ‘‘any sharpness,’’
and if they do, whether it is ‘‘as sharp as they would expect.’’ This is
performed on both lower limbs. The lower limbs are divided into 6
regions for testing; 2 points are scored for each region in which the
subject fails to feel any sharpness. This is conducted and scored on
both lower limbs. One additional point is scored for each additional
region in which the pin feels less sharp than expected. Vibration is
tested using a 128 Hz tuning fork maximally struck and applied to
the dorsum of the great toe at the interphalangeal joint.
The UENS has also been correlated with data from electrophys-
iological and QST testing [61]. The UENS has recently been used in
a small HIV-SN population, where it was shown to correlate with
autonomic dysfunction measures (quantitative sudomotor axon
reﬂex testing) and pain severity, but it was not validated for the
diagnosis of HIV-SN [6].
2.7. Pain symptomatology, sleep disturbance, quality-of-life, and
psychological comorbidity measures
Participants were given a questionnaire pack to complete and
return to the investigation centre after their clinical assessment
appointment. For the purpose of the questionnaires, participantswere asked to consider any pain they were experiencing or the last
time they had experienced pain. The body site was not
prespeciﬁed.
Seven-day pain diary. Patients were asked to keep a pain inten-
sity diary for 7 days, recording pain at 8 am and 8 pm daily on an
11 point scale, with 0 being no pain and 10 the worst pain
imaginable.
Neuropathic Pain Symptom Inventory (NPSI). The NPSI is a vali-
dated self-administered questionnaire designed to evaluate neuro-
pathic pain symptomatology [7]. It evaluates the presence and
severity of 10 different neuropathic pain descriptors, each on an
11 point scale where 0 indicates no symptoms and 10 indicates
maximal symptoms experienced. The NPSI also includes 2 tempo-
ral items assessing the duration of spontaneous ongoing pain, and
the number of pain attacks on 5-point categorical scales; these
temporal scores were not used in the ﬁnal analysis. NPSI descriptor
responses were divided into mild (0–3), moderate (4–6), and
severe (7–10), and the proportion of participants experiencing
each was determined [24].
Spearman correlation analysis was performed to assess correla-
tions between QST and NPSI domains; responses were considered
correlated if r > 0.3 and P < .0001.
Brief Pain Inventory (BPI) 7-item pain interference subscale. Pain-
related interference in activities of daily living was assessed using
the 7-item Pain Interference scale of the BPI [15]. The scale
assesses pain interference within 7 domains: general activity,
walking, work, relationships, mood, life enjoyment, and sleep. Par-
ticipants score these on a 11 point scale ranging from 0 (does not
interfere) to 10 (completely interferes). The composite score was
calculated as the sum of the 7 interference items. Validity for the
BPI comes from several studies of cancer pain and other diseases
of pain. The BPI also demonstrates good test–retest item correla-
tions over short time intervals [15,19].
SF-36 instrument. Short Form 36 of the MOS Outcomes Study
(SF-36) is an established instrument used for the assessment of
health-related quality of life [70]. SF-36 responses were scored in
the 8 domains of physical functioning: role–physical, bodily pain,
general health, vitality, social functioning, role–emotional, and
mental health. SF-36 scores range from 0 to 100, representing
extreme dysfunction/symptom severity to optimal function,
respectively. Published reliability statistics for the SF-36 for inter-
nal consistency and test–retesting have exceeded the minimum
standard of 0.70 in group comparisons in more than 25 studies
[63]. Relative to the longer measures that the SF-36 was con-
structed to reproduce, SF-36 scales have been shown to achieve
about 80% to 90% of their empirical validity in studies involving
physical and mental health criteria [44].
Pain Anxiety Symptom Scale 20 (PASS-20). Pain-related anxiety
was assessed with the PASS-20 [42], which is a shortened version
of the PASS [43]. PASS-20 has 20 questions assessing 4 facets of
pain-related anxiety: fearfulness of pain, cognitive anxiety,
escape/avoidance, and psychological anxiety. Each subscale score
ranges from 0 (no interference) to 25 (maximum interference).
Additionally, summation of the subscales provides a general mea-
sure of pain-related anxiety. The original long version of the PASS
has been shown to correlate with measures of pain-related anxiety
and fear [42]. The shortened PASS-20 scale has been shown to have
a similar performance to the original PASS across the shortened
and corresponding matching original scales (mean r = 0.95); the
scale also has high internal consistency through item intercorrela-
tions (mean a = 0.81).
Amended Depression Anxiety Positive-Outlook instrument (DAPOS).
We used the depression and anxiety subscales of the DAPOS instru-
ment [52]. This instrument was designed to measure mood specif-
ically in pain populations and consists of 3 subscales. The subscale
for depression (DAPOS-D) contains 5 items with scores ranging
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subscale for anxiety (DAPOS-A) contains 3 items, which ranges
from 3 to 15 (no anxiety to maximal anxiety). The positive outlook
component was omitted. The DAPOS has shown good internal con-
sistency, with a ranging from 0.74 to 0.90. The DAPOS has also
been shown to have good construct validity in comparison to
several established measures (SF-36, Pain Catastrophizing Scale,
Hospital Anxiety and Depression Scale (HADS) and Zung depression
scale) [51,52].
Pain Catastrophizing Scale (PCS). The PCS assesses the cognitive
process by which pain is appraised in terms of threat and negative
consequences [47]. It consists of 13 descriptions of thoughts and
feelings related to pain. Respondents are asked to indicate the
degree to which they experience these on a 5-point rating scale
from 0 (not at all) to 4 (always). A high total score indicates a high
level of pain catastrophizing. The instrument comprises 3 dimen-
sions: rumination, magniﬁcation, and helplessness. Rumination
refers to the patients’ preoccupation with pain; magniﬁcation
expresses the exaggerated cognitions of pain as a threat; and hope-
lessness is patients’ feelings that they are unable to inﬂuence their
pain. The PCS has been shown to have a high internal consistency
and validity, with a high test–retest correlation (r = 0.75) over a
6-week interval in the same individual [47].
Insomnia Severity Index (ISI). To assess the prevalence of sleep
dysfunction, we used the ISI [5]. The ISI was speciﬁcally designed
to assess insomnia and is a brief self-report instrument, which
measures a patient’s perception, subjective symptoms, and conse-
quences of their insomnia. Its content corresponds, in part, to the
diagnostic criteria of insomnia. The ISI is composed of 7 items
assessing the severity of sleep onset and sleep maintenance difﬁ-
culties, satisfaction with sleep patterns, interference with daily
functioning, noticeability of impairment due to sleep dysfunction,
and the degree of distress experienced by the patient.Table 1
Demographics, characteristics, and comorbidities of patients in HIV-SN and HIV–No
SN groups.a
Characteristic HIV–No SN (n = 38) HIV-SN (n = 28) P
Age, y 47.7 ± 8.9 51.3 ± 8.4 .097
Male 32 (84.2 %) 25 (89.3%) .553
Height, cm 175.1 ± 8.8 177.1 ± 7.8 .321
Weight, kg 77.1 ± 15.1 80.5 ± 12.2 .334
Years since HIV diagnosis 14.7 ± 7.8 17.8 ± 7.0 .0942.8. Case deﬁnition of HIV-SN
Different case deﬁnitions have been proposed and used in ear-
lier investigations of HIV-SN [8,22,62]. Most previous HIV-SN stud-
ies have assessed a combination of symptoms and basic clinical
signs to detect peripheral neuropathies. The absence of a gold-
standard deﬁnition for HIV-SN and for other small ﬁbre neuropa-
thies has been identiﬁed as a factor hindering progress in
understanding HIV-SN [23] and small ﬁbre neuropathy (SFN) path-
ophysiologies per se [20]. In this study, we propose a deﬁnition of
HIV-SN using the criterion of 2 or more out of the following 3
items: clinical signs of distal sensory neuropathy elicited using
the SNE, 2 or more abnormal QST ﬁndings using the full 13 param-
eters of the DFNS protocol, and intraepidermal nerve ﬁbre density
of 67.63 ﬁbres/mm on skin sample examination. Such a composite
deﬁnition has been previously proposed for use in the study of
other small ﬁbre neuropathies, but not in HIV-SN [20].Ethnicity
White European, % 33 (86.8%) 24 (85.7%) .553
African origin, % 4 (10.5%) 3 (10.7%) .553
Asian, % 1 (2.6%) 0 (0%) .553
Mixed ethnicity, % 0 (0%) 1 (3.6%) .553
Comorbidities
Type II diabetesb 3 (7.9%) 5 (17.9%) .220
Hepatitis C infection 9 (23.7%) 6 (21.4%) .829
Hepatitis B infection 3 (7.9%) 5 (17.7%) .220
Syphilis 6 (15.8%) 4 (14.3%) .497
Chemotherapy exposure 1 (2.6%) 3 (10.7%) .174
HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy.
a Continuous data, if normally distributed, were analysed by Student’s t test, and
mean ± SD are shown. Categorical data were analysed by v2 test of association;
values and percentages are shown.
b No participants with type I diabetes.2.9. Sample size
At the time of the study there were few data available regarding
the diagnostic value for HIV-SN for each of the 2 primary measure-
ments of interest (QST and IENFD) on which to base a sample size
calculation. Nevertheless, such a calculation in relation to these
measures has been performed in order to guide study conduct
(t test for power calculation, Sigma v 3.5, Systat Software Inc.).
For QST, theDWDT data for HIV positive patients verses healthy
controls from Martin et al. [41] were used. This calculation
revealed a minimum sample size of 11 was required per group
for a power of >0.8 (power 0.828; difference in means 4.3; standard
deviation 3.3; a = 0.05).For IENFD, data for patients with small ﬁbre neuropathies vs
healthy controls from Nebuchennykh et al. [46] were used. This
calculation revealed a minimum sample size of 16 was required
per group for a power of >0.8 (power 0.816; difference in means
4.7; standard deviation 4.5; a = 0.05).
However, because of the uncertain assumptions inherent in
such calculations, a minimum group size of 25 was used.
3. Results
3.1. Participants
Between July 7, 2009, and January 25, 2011, a total of 66 HIV-
positive subjects participated in the study. All were ambulatory
patients attending the St Stephen’s Centre, Chelsea and Westmin-
ster Hospital, London. All 66 participants attended the clinical
assessment, but for 2 participants (one from the HIV-SN group
and the other from the HIV–No SN group) thermal parameters
were missing from the QST data set as a result of an isolated equip-
ment malfunction. Data from these subjects are excluded from the
thermal QST data analysis. No participants were excluded by the
criterion of pain scored as P4 of 10 on an NRS from a cause other
than SN.
IENFD were determined on 57 participants out of the total 66.
Six participants did not consent to undergo skin biopsy (4 from
the HIV–No SN group and 2 from the HIV-SN group), and 1 partic-
ipant from the HIV-SN group was receiving anticoagulation ther-
apy (warfarin), and thus skin biopsy was contraindicated. Two
samples (1 from each group) were of insufﬁcient quality to allow
IENFD determination. Participants with missing IENFD data were
not included in the IENFD data analysis.
3.2. Demographics
Participant demographic data are presented in Table 1. The
HIV–No SN and HIV-SN groups were evenly matched in terms of
demographic and related clinical factors. The majority of partici-
pants were white (86.4%), male (86.4%), and middle-aged
(mean ± SD age, 49.2 ± 8.8 years), broadly reﬂecting the patient
population of the recruitment centre in the current cART era
(Dr Marta Bofﬁto and Dr David Asboe, personal communication).
Table 2








ARV therapy 36 (94.74%) 28 (100%) .218
Years receiving ARV
therapy
9.90 ± 6.43 11.77 ± 5.90 .361b
dNRTI
Ever received dNRTI 20 (52.63%) 20 (71.43%) .122
Years receiving dNRTI 12.89 ± 2.32 12.63 ± 3.72 .989b
ddC
Ever received ddC 4 (10.53%) 6 (21.43%) .222
Years receiving ddC 14.90 ± 1.68 16.54 ± 1.50 .142
d4T
Ever received d4T 18 (47.37%) 17 (60.71%) .283
Years receiving d4T 12.02 ± 1.40 12.31 ± 1.77 .577
ddI
Ever received ddI 12 (31.58%) 14 (50.00%) .130
Years receiving ddI 11.49 ± 2.84 10.81 ± 3.35 .579
NRTIsc
Ever received NRTIs 36 (94.74%) 27 (96.43%) .744
Years receiving NRTIs 9.15 ± 6.45 11.99 ± 4.99 .053
NNRTIs
Ever received NNRTIs 28 (73.68%) 25 (92.59%) .115
Years receiving NNRTIs 8.17 ± 6.53 10.53 ± 6.53 .192
PI
Ever received PI 21 (55.26%) 21 (75.00%) .099
Years receiving PI 21.56 ± 14.02 28.55 ± 21.10 .687b
IDV
Ever received IVD 5 (13.16%) 9 (32.14%) .062
Years receiving IDV 13.28 ± 0.68 12.64 ± 1.15 .280
HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy; ARV,
antiretroviral therapy; dNRTI, deoxy nucleoside reverse transcriptase inhibitors;
ddC, zalcitabine; d4T, stavudine; ddI, didanosine; NNRTI, nonnucleoside reverse
transcriptase inhibitors; PI, protease inhibitor; IVD, indinavir.
a Continuous data, if normally distributed, were analysed by Student’s t test, and
mean ± SD are shown. Continuous data not normally distributed were analysed by
Mann-Whitney rank sum test. Categorical data were analysed by v2 test of asso-
ciation; values and percentages are shown.
b Not normally distributed.
c All NRTIs, including dNRTIs.
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lished, the study group was divided into HIV-SN and HIV–No SN
groups; 28 participants (42.4%) were thus allocated to the HIV-
SN group and 38 (57.6%) to the HIV–No SN group. Twenty-one of
the 28 (75.0%) HIV-SN patients reported persistent pain in a distal
symmetrical anatomical distribution consistent with a neuropathy.
There was no signiﬁcant difference between the HIV-SN and HIV–
No SN groups in terms of sex, ethnicity, height, weight, age, or
years since HIV diagnosis. A potential limitation of using the trium-
virate is that each of the factors used in the case deﬁnition was also
examined in the proﬁling. We examine this further below, and
we provide a post hoc analysis of the impact of each factor on
participant group allocation.
There was no difference between the 2 groups for the frequency
of comorbidities which are associated with other risk factors for
peripheral neuropathy (diabetes mellitus, hepatitis B and C, syph-
ilis, or exposure to chemotherapy agents).
3.3. QST healthy control participants
Control data from healthy subjects were collected to meet the
DFNS requirements for quality assurance and to provide normal
values for suprathreshold heat responses. Thirty-six healthy sub-
jects were recruited with a mean ± SD age of 34.60 ± 9.45 years,
21 (58.3%) of whom were male. These participants underwent
the DFNS QST protocol, after which the additional suprathreshold
heat testing was conducted on each.
3.4. History of ARV therapy
The histories of participants’ ARV therapy are presented in
Table 2. Only 2 participants (3.0%) had no previous exposure to
ARV drugs; both were in the HIV–No SN group. The majority had
previous ARV drug exposure and were all currently receiving cART
(n = 64, 97.0%). No statistical difference was observed between the
2 groups for either individual agents or for classes of agents in rela-
tion to exposure or mean years exposed. There was also no differ-
ence between the 2 groups for the total number of drug-years for
which a patient received a class of agent or the maximum number
of consecutive years of exposure to a given drug class (data not
shown).
There was no statistical difference between the 2 groups for
exposure to dNRTI agents; 52% (HIV–No SN) and 71% (HIV-SN) of
participants had been exposed at some point to neurotoxic dNRTIs
(P = .122), and the mean exposure was about 12 years. This was
independent of time since HIV diagnosis. The groups were also
matched for exposure to the potentially neurotoxic protease inhib-
itor indinavir [12,22,49,62], with 13% (HIV–No SN) and 32% (HIV-
SN) of subjects having been exposed to the drug for a mean of
about 13 years.
3.5. Quantitative sensory testing
Distribution of mean QST z-scores across groups. The data for ther-
mal QST parameters are presented in Fig. 1 and Supplementary
Document 4. The mean z-scores for all thermal parameters fall
within the DFNS normative range, although data from individual
patients are seen outside the normative range, especially for CDT,
WDT, and HPT in the HIV-SN group (Fig. 1). However, between-
group comparisons (Fig. 1) reveal signiﬁcant differences, in the
loss-of-function direction, between the locally recruited healthy
control groups and the HIV–No SN and HIV-SN groups (P < .05,
Kruskal-Wallis, Dunn’s post hoc test). This general shift across all
thermal parameters towards hypoesthesia was largest in the
HIV-SN group. Mean z-score values, when compared to the DFNS
normative data set, reveal a loss of function for MDT and VDT inthe HIV-SN group (Supplementary Document 4). No such effect
was observed for the other mechanical sensory parameters. This
loss of sensation was also reﬂected when data for these parameters
were compared with those obtained from locally recruited healthy
controls (Fig. 2; P < .05, Kruskal-Wallis, Dunn post hoc test).
Supplementary Document 4 shows that mean healthy control
QST participant data closely match that predicted by DFNS control
values for 12 of the 13 DFNS QST parameters. This is indicated by
the z-transformed QST mean values in the healthy control group
all being close to 0, with SDs of near to 1 or less. MPS values in
healthy control subjects showed a slight shift in mean values com-
pared to DFNS data, with 5 (13.9%) participants showing abnormal
values compared to DFNS healthy control data.
Frequency of individual QST measure abnormalities: loss and gain
of sensory function. The frequency of abnormal QST values in each
group are shown in Fig. 2 and Supplementary Document 4. The
majority of abnormal parameters were loss of sensory function
for any of the QST parameters, with 34.2% and 85.7% of participants
in the HIV–No SN and HIV-SN groups, respectively, displaying evi-
dence of at least 1 abnormal value. There was no difference
between the groups in the number of participants in whom gain-
of-function phenomena were observed: 26.3% in HIV–No SN,
28.6% in HIV-SN, and 30.6% of healthy controls. The most frequent
sensory abnormalities seen in the HIV-SN group were loss of MDT
Fig. 1. Dot plot of z-score QST parameters in the healthy control, HIV–No SN and HIV-SN groups for Mechanical QST parameters (A) and Thermal QST parameters (B).
⁄Kruskal-Wallis, Dunn’s post hoc 1-way analysis of variance: ⁄P < .05; NS, P > .05. QST, quantitative sensory testing; HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV
sensory neuropathy; NS, not signiﬁcant.
Fig. 2. Loss and gain of sensory function. Comparison of participants in the HIV-SN group, HIV–No SN group, and healthy controls who have QST values outside the 95%
conﬁdence interval of the DFNS reference database. The y-axis shows the percentage of patients in each group (HIV-SN n = 38, HIV–No SN n = 28, healthy controls n = 36),
with ‘gain’ of sensory function plotted upwards and ‘loss’ of sensory function plotted downwards. HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy;
QST, quantitative sensory testing; HIV–No SN, no HIV sensory neuropathy. Chi squared test of association: * P < 0.05, ** P < 0.01 comparison to Healthy controls;  P < 0.05,
 P < 0.01 comparison to HIV-No SN.




Frequency of different patterns of sensory loss and gain in HIV-SN group (n = 28).
Characteristic Gain 0 Gain 1 Gain 2 Gain 3 Gain, all
Loss 0 4 (14.3%) 0 0 0 4 (14.3%)
Loss 1 0 0 0 0 0
Loss 2 6 (21.4%) 0 4 (14.3%) 0 10 (35.7%)
Loss 3 12 (42.9%) 0 2 (7.1%) 0 14 (50%)
Loss, all 22 (78.6%) 0 6 (21.4%) 0 28 (100%)
Loss 0, no loss of detection; Loss 1, loss of only thermal loss; Loss 2, loss of only
mechanical; Loss 3, loss of both thermal and mechanical; Gain 0, no gain of
detection; Gain 1, gain of only thermal; Gain 2, gain of only mechanical; Gain 3, gain
of thermal and mechanical.
Fig. 3. Pain intensity response curves for suprathreshold heat stimuli in healthy
control subjects (n = 36), HIV–No SN group (n = 38), and HIV-SN (n = 28) group. Data
are presented as mean (SD). No statistically signiﬁcant difference was present
between groups. VAS, visual analogue scale; HIV-SN, HIV sensory neuropathy;
HIV–No SN, no HIV sensory neuropathy.
T.J.C. Phillips et al. / PAIN

155 (2014) 1846–1860 1853and VDT, both of which were independently abnormal in 50.0%,
with 32.14% demonstrating the loss of both in the HIV-SN group.
In contrast, in the healthy control group and the HIV–No SN group,
sensory loss for MDT was found in only 5.6% and 5.3%, and for VDT
in 5.6% and 10.5%, respectively.
Within thermal sensory parameters, the HIV-SN participants
showed a loss of CDT function (28.6%) most frequently (compared
to 5.3% in the HIV–No SN group), followed by WDT and TSL (14.3%
and 2.6% in both HIV groups). Loss of HPT was the most frequent
abnormal thermal nociceptive parameter in the HIV-SN group
(32.1%) and in the HIV–No SN group (7.9%). No participant in either
HIV group displayed abnormalities of CPT. The presence of PHS was
considered a loss of thermal discrimination and therefore a loss of
sensory function [57]. PHS phenomena were observed in 7.9% and
14.3% of the HIV–No SN and HIV-SN groups, respectively.
The presence of gain-of-sensory function was rare across all
groups but was seen most frequently in the mechanical WUR
parameter, with 14.3% of HIV-SN patients demonstrating it com-
pared to only 5.3% and 5.6% of the healthy control and HIV–No
SN groups (P < .05,v2 test of association against HIV–No SN group).
Examination of the dot plots in Fig. 1 reveals a potential subset of 4
HIV-SN participants who are characterised by high (gain of func-
tion) z-scores for WUR (P < .05, v2 test of association compared
to HIV–No SN group). No participants in any of the groups were
found to have DMA.
Patterns of loss and gain of sensory function. HIV-SN-associated
abnormalities in QST parameters were dominated by loss of sen-
sory function effects (Table 3). Indeed, the majority of HIV-SN par-
ticipants (85.7%) had at least 1 abnormality on QST testing and had,
at a minimum, loss of 1 sensory parameter. Different combinations
of sensory loss and gain did occur across the HIV-SN group; how-
ever, the majority involved just sensory loss
(L1 + L2 + L3 = 78.6%). The most frequent combination was the loss
of at least 1 thermal and 1 mechanical QST parameter in 42.9% of
participants (L3G0). HIV–No SN participants demonstrated loss or
gain of thermal modalities in isolation (L1 or G1) (Table 3). The sec-
ond most frequent combination was loss of just mechanical sen-
sory modalities (L2G0, 21.4%).
Suprathreshold heat testing. Fig. 3 displays the cumulative mean
pain intensity responses to suprathreshold heat stimuli in the
range between 48C and 52C for the 3 groups: healthy controls,
HIV–No SN group, and HIV-SN group. Healthy control patients
had an earlier take-off point in pain visual analogue scale (VAS)
responses—that is, this occurred at lower temperatures. However,
at higher suprathreshold temperatures, there was little difference
in the VAS responses elicited from all the 3 groups tested. No sta-
tistically signiﬁcant difference was seen between the 3 groups or in
the painful HIV-SN subgroup of HIV-SN (data not shown) for pain
response at any suprathreshold temperature.
3.6. Intraepidermal ﬁbre densities
A total of 57 skin punch biopsy samples were available for IEN-
FD measurement from the 66 participants. Fig. 4 shows represen-
tative images of 2 participants, one with reduced IENFD counts
(Fig. 4A) and the other with normal ﬁbre counts (Fig. 4B).
The associated intraobserver correlation coefﬁcients for 20 ran-
domly selected samples for quality assurance exercise was 0.88
(JDR) and 0.89 (MB), both of which are high. A high interobserver
Pearson’s product-moment correlation coefﬁcient of 0.93 was
determined between the 2 microscopists (JDR and MB) for all
(n = 55) study samples.
The median values of IENFD for HIV–No SN group was
9.2 ﬁbres/mm (range 1.7–14.4 ﬁbres/mm) compared to 6.3 ﬁbres/
mm (range 0.7–12.4 ﬁbres/mm) for the HIV-SN group (P < .001).
In accordance with previously published literature, an IENFD valueof <7.63 ﬁbres/mm was taken as being abnormal [35]; this was
seen in 8 (21.1%) of the HIV–No SN group and 17 (60.7%) in the
HIV-SN group (P < .05), with an associated sensitivity and speciﬁc-
ity of detecting HIV-SN in isolation of 61% and 79%. This result
might be expected, given the case deﬁnition used.
Supplementary Document 5 provides Pearson’s correlation coef-
ﬁcients for individual QST parameters and IENFD. No correlation
between the measured QST parameters and IENFD was observed.
As would be expected, IENFD was inversely correlated to the
severity of the peripheral neuropathy as measured by the TCSS
instrument (r = 0.343, 95% conﬁdence interval 0.56 to 0.88,
P < .01).
3.7. Pain and patient-reported symptoms
Results of the structured patient symptom and medical history
interview, and the 7-day pain diary are presented in Table 4.
More participants reported pain in their hands and/or feet in
the HIV-SN group compared to HIV–No SN group (75.00% vs
28.95% respectively, P < .001). The mean ± SD 7-day pain intensity
score for patients experiencing pain was also greater (P < .001) in
the HIV-SN group (5.65 ± 1.76) compared to the HIV–No SN group
(2.8 ± 2.34). The mean number of years from HIV diagnosis and the
mean duration of pain were similar in the 2 groups. Although there
was no difference between groups in the reporting of ‘pins and
needles’, the reporting of ‘numbness’ in feet and/or hands was
more frequent in the HIV-SN group (75.0%) compared to the
HIV–No SN group (36.8%, P < .05).
3.8. NPSI
Individual participant responses to the 10 NPSI items were
divided into mild, moderate, and severe and are shown in Fig. 5
Fig. 4. Two representative skin biopsy samples of HIV-infected participants. (A) Participant from HIV-SN peripheral neuropathy group demonstrating complete absence of
small unmyelinated sensory nerve ﬁbres reaching epidermis. Subepidermal dermal plexus ﬁbres are present (blue arrow) as identiﬁed by pan neuronal marker PGP 9.5. (B)
Participant from HIV–No SN group with normal counts of small unmyelinated nerve ﬁbres (black arrows) reaching epidermis beyond dermal epidermal junction (red dotted
line), and positive dermal plexus staining (blue arrows). Original magniﬁcation, 40. Scale bar = 50 lm. HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory
neuropathy.
Table 4
Comparison of participant reported symptoms between HIV-SN and HIV–No SN groups.a
Reported symptom HIV–No SN (n = 38) HIV-SN (n = 28) P
Any pain in hands and/or feet 11 (28.95%) 21 (75.00%) <.001
If experiencing pain: 7-d pain diary, NRS (0–10) 2.81 ± 2.34 5.65 ± 1.76 <.001
Pain onset, y after HIV diagnosis 12.29 ± 5.94 9.50 ± 7.59 .358
Pain duration, y 9.50 ± 7.59 8.25 ± 7.23 .811
‘Pins and needles’ in feet and/or hands 19 (50.00%) 17 (60.71%) .388
‘Numbness’ in feet and/or hands 14 (36.84%) 21 (75.00%) <.02
Perceived ‘weakness’ in upper or lower limbs 10 (26.32%) 10 (35.71%) .412
Postural hypotension 9 (24.68%) 14 (50.00%) <.02
Urinary dysfunction 6 (15.79%) 12 (42.86%) <.02
Erectile dysfunction 12 (31.58%) 14 (50.00%) .152
Nocturnal diarrhoea 10 (26.32%) 8 (28.57%) .839
HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy; NRS, numerical rating scale.
a Continuous data, if normally distributed, were analysed by Student’s t test, and mean ± SD are shown. Categorical data were analysed by v2 test of association; values and
percentages are shown.
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shown in Supplementary Document 6.
Of the 7 nonevoked pain items, more than 50% of participants
reported moderate to severe symptoms for all of these, except
‘squeezing pain’ (36%). ‘Burning’ was the most frequently reported
as being moderate or severe; however, ‘tingling’ was the most fre-
quently reported as being severe (63%).
Of the 3 evoked pain items, ‘pressure evoked’ was most often
reported as being moderate or severe (68%), followed by ‘cold
evoked’ (42%) and ‘brush evoked’ (26%).
No correlations were seen between the descriptive NPSI scores
and QST values.
3.9. Autonomic function
More participants with HIV-SN compared to those without HIV-
SN, reported experiencing symptoms of postural hypotension
(50.0% vs 24.6% respectively, P < .01); however, participants’
reported symptoms of orthostatic hypotension correlated to mea-
sured orthostatic hypotension in only 33.3% of HIV–No SN and
7.1% of HIV-SN participants. No difference was seen in measured
orthostatic hypotension between the 2 groups (14.8% vs 18.4%
for HIV-SN and HIV–No SN groups, respectively; P = .702).
Patients reported symptoms of urinary dysfunction more
frequently in the HIV-SN group (42.9%) compared to the HIV–No
SN group (15.8%, P < .05). The frequency of participants reportingerectile dysfunction and nocturnal diarrhoea were similar for both
groups (Table 4).
3.10. Psychological problems, sleep disturbance, and health-related
quality of life
Results from the psychological and insomnia instrument bat-
tery are presented in Table 5. Of the 66 participants, 57 (86.3%)
returned completed questionnaire booklets to the test centre for
analysis. The return of questionnaires and completion of individual
scores within each group are shown in Supplementary Document
7. We had planned a comparison of HIV-SN without pain and
HIV-SN with pain to the participants without neuropathy (HIV–
No SN). However only a small number of participants with HIV-
SN with no pain (7 individuals) were found, making a comparison
unlikely to be meaningful. These individuals were not included (as
part of the HIV-SN group) in the analysis of psychological instru-
ments, insomnia, or health-related quality of life, as their presence
could potentially confound the inﬂuence of pain in the HIV-SN
group when comparing it to the HIV–No SN group.
3.11. Pain interference and health-related quality of life
As expected, the BPI interference subscale mean total score was
signiﬁcantly higher in the painful HIV-SN group compared to the
HIV–No SN group. The high scores present in the painful HIV-SN
Fig. 5. Distribution of NPSI descriptors in the painful HIV-SN population divided by categories of severity. NPSI, Neuropathic Pain Symptom Inventory; HIV-SN, HIV sensory
neuropathy.
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mental impact on their day-to-day living and their quality of life.
The SF-36 data further establish that participants with painful
HIV-SN experienced signiﬁcantly more difﬁculties compared to
the HIV–No SN group across all of the domains of the SF-36
(Table 5). In particular, HIV-SN patients’ physical functioning, per-
ceptions of their physical selves, general vitality, and social func-
tioning are poorer in the painful HIV-SN group compared to
patients in the HIV–No SN group.
3.12. Sleep dysfunction
Analysis of data from the self-report ISI instrument indicated
that both patient groups on average experienced mild subclinical
insomnia; at the group level, there was no independent effect of
HIV-SN. At the individual level, more participants in the painful
HIV-SN group reported sleep disturbance equating to clinical
insomnia (ISIP 15); almost twice as many participants in the
HIV-SN group experienced severe insomnia (ISIP 22).
3.13. Depression, anxiety, and catastrophizing
Participants with painful HIV-SN were more depressed and anx-
ious as measured by the DAPOS than those in the HIV–No SN group
(Table 5).Overall, there was no difference between the groups with
regard to the total PASS-20 scores (Table 5). However, differences
were evident in the speciﬁc domains of the PASS-20. The HIV-SN
group reported more features of cognitive impairment in response
to pain compared to the HIV–No SN group. There was more phys-
iological anxiety and fear as measured with the PASS-20 subscales
in the painful HIV-SN group compared to the HIV–No SN group.
There was a difference between the groups for catastrophizing
(Table 5): mean ± SD 14.3 ± 11.81 in the HIV–No SN group com-
pared to 23.74 ± 12.64 in the painful HIV-SN group (P = .009). This
difference was largely attributable to a difference in the PCS help-
lessness subscale.
3.14. Plasma lipid proﬁles, random glucose, body mass index, and
waist–hip circumference ratios
A higher mean triglyceride plasma (TRG) concentration was
measured in the HIV-SN group 2.18 ± 1.09 mmol/L compared to
that for the HIV–No SN group, at 1.61 ± 0.77 mmol/L (P < .05;
Table 6). There was no signiﬁcant difference between the 2 groups
in statin drug use. Despite this difference in TRG concentrations,
we did not ﬁnd a correlation between the severity of neuropathy
(using the TCSS instrument) and plasma TRG concentrations
(rs = 0.155, 95% CI [0.514 to 0.250], P = .439). No signiﬁcant dif-
ferences were found between the 2 groups for other plasma lipids,
Table 5
Summary of sleep and psychological instruments results comparing HIV–No SN and painful HIV-SN.
Instrument HIV–No SN (n = 38) HIV-SN with pain (n = 21) P
ISI
Mean ISI total score (/28) 10.16 ± 7.86 14.05 ± 8.86 .112
Participants with clinical insomnia (ISI P15) 7 (22.6%) 13 (68.4%) <.001
Participants with severe insomnia (ISI P22) 3 (9.7%) 7 (22.6%) <.001
DAPOS
DAPOS depression (/25) 8.38 ± 4.10 11.21 ± 4.22 <.05
DAPOS anxiety (/15) 5.45 ± 2.89 7.47 ± 2.97 <.05
PASS-20
PASS cognitive (/25) 8.45 ± 5.28 14.95 ± 5.69 <.001
PASS escape-avoidance (/25) 9.07 ± 7.15 11.84 ± 6.38 .177
PASS fear (/25) 6.97 ± 7.11 11.79 ± 6.75 <.05
PASS physiological anxiety (/25) 4.83 ± 6.45 9.21 ± 7.54 <.05
PASS total (/100) 35.84 ± 29.84 47.79 ± 21.94 .136
PCS
PCS rumination (/16) 5.68 ± 4.85 8.84 ± 5.11 0.330
PCS magniﬁcation (/12) 3.97 ± 3.66 5.63 ± 3.39 .115
PCS helplessness (/24) 6.03 ± 5.52 11.16 ± 6.131 <.02
PCS total (/52) 14.13 ± 11.81 23.74 ± 12.64 <.02
BPI
BPI interference (/70) 15.20 ± 16.22 46.11 ± 13.69 <.001
SF-36
Physical Functioning (PF) 74.03 ± 24.65 34.47 ± 21.74 <.001
Role Physical (RP) 50.78 ± 43.76 11.84 ± 28.10 <.001
Bodily Pain (BP) 69.43 ± 24.47 29.42 ± 18.06 <.001
General Health (GH) 43.78 ± 26.96 26.58 ± 19.88 <.05
Vitality (VT) 49.53 ± 24.08 25.79 ± 24.45 <.001
Social Functioning (SF) 67.98 ± 27.31 32.24 ± 24.41 <.001
Role Emotional (RE) 54.17 ± 46.18 15.79 ± 32.14 <.05
Mental Health (MH) 63.25 ± 21.25 47.79 ± 17.05 <.05
HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy; ISI, Insomnia Severity Index; DAPOS, Depression Anxiety Positive Outlook Scale; PASS-20, Pain
Anxiety Symptom Scale Short Form; PCS, Pain Catastrophizing Scale; SF-36, Short Form (36) Health Survey.
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were on the upper end of normal (Table 6).
3.15. Peripheral neuropathy screening and severity instruments: BPNS,
UENS, and TCSS
Mean scores were determined and receiver operating character-
istic (ROC) plots generated for each of the 3 neuropathy screening
instruments examined in the study. Optimal cutoff values for the
diagnosis of HIV-SN in the study population were determined from
these plots, giving equal weight for sensitivity and speciﬁcity.Table 6
Comparison of various metabolic factors in HIV–No SN and HIV-SN groups.a





Total cholesterol, mmol/L 4.56 ± 1.08 5.01 ± 1.07 .100
Triglycerides, mmol/L 1.61 ± 0.77 2.18 ± 1.09 <.020b
HDL, mmol/L 1.06 ± 0.36 1.24 ± 0.44 .069
LDL, mmol/L 2.75 ± 0.93 2.71 ± 0.95 .860
Cholesterol:HDL ratio 4.53 ± 1.57 4.42 ± 1.27 .769
Random glucose, mmol/L 5.31 ± 1.20 5.31 ± 1.07 .863b
BMI, kg/m2 25.28 ± 5.34 25.68 ± 3.69 .223b
Waist–hip circumference
ratio
0.98 ± 0.09 0.96 ± 0.12 .739b
Current statin use 9 (23.70%) 9 (32.14%) .446
HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index.
a Continuous data, if normally distributed, were analysed by Student’s t test, and
mean ± SD are shown. Continuous data not normally distributed were analysed by
Mann-Whitney rank sum test. Categorical data were analysed by v2 test of asso-
ciation; values and percentages are shown.
b Not normally distributed.Using the BPNS scoring method described by Cherry et al. [14]
(which weights loss of deep tendon reﬂexes and vibration percep-
tion measures), the BPNS instrument has a speciﬁcity and sensitiv-
ity in the detection of HIV-SN of 75% and 79% (P < .001). When the
numerical component of the BPNS is used in its raw form, weight-
ing sensitivity and speciﬁcity equally, a cutoff value of 19 is asso-
ciated with sensitivity and speciﬁcity of 76%.
The mean ± SD TCSS values for HIV–No SN compared to HIV-SN
were 3.36 ± 3.65 and 9.26 ± 3.28, respectively (P < .001). ROC
analysis found a value of 8 provided the best accuracy in HIV-SN
detection; sensitivity and speciﬁcity were 79%.
The UENS median ± SD values for HIV–No SN compared to HIV-
SN group were 3.64 ± 2.98 and 11.26 ± 5.66, respectively (P < .001).
The original validation study for the UENS did not suggest a cutoff
score for the diagnosis of a peripheral neuropathy; giving equal
weight to sensitivity and speciﬁcity, a value of 7 was selected in
this current study. This provides a sensitivity and speciﬁcity of
84% in detection of HIV-SN.
Using the ROC plots for each instrument, area under the curve
(AUC) was used as a measure of accuracy, with a larger AUC equat-
ing to greater accuracy. The instrument found to have the greatest
accuracy was the UENS (AUC 0.91), followed by TCSS (AUC 0.86)
and then the BPNS (AUC 0.69).
3.16. Testing the HIV-SN triumvirate deﬁnition
As this study’s case deﬁnition of HIV-SN used a triumvirate uti-
lising QST, IENFD and a SNE, we tested the consequences of using
different combinations of the triumvirate on the HIV-SN designa-
tion of participants in the study (Table 7). Removal of QST and IEN-
FD individually from the triumvirate resulted in sensitivity and
speciﬁcity of 71%, 100% and 79%, and 100%, respectively, when
Table 7
Comparison of the use of different combinations of the triumvirate criteria for diagnosis of HIV-SN.a
Changed diagnosis QST + CNE + IENFD QST + CNE QST + IENFD CNE + IENFD QST CNE IENFD
‘HIV–No SN’ changed to ‘HIV-SN’, n (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 7 (18.42%) 10 (26.32%) 8 (21.05%)
‘HIV-SN’ changed to ‘HIV–No SN’, n (%) 0 (0%) 6 (21.43%) 17 (60.07%) 8 (28.57%) 6 (21.43%) 0 (0%) 11 (39.29%)
No. changed (% of total participants) 0 (0%) 6 (9.09%) 17 (25.76%) 8 (12.12%) 13 (19.70%) 10 (15.15%) 19 (28.79%)
Sensitivityb 1.000 0.786 0.393 0.714 0.786 1.000 0.607
Speciﬁcityb 1.000 1.000 1.000 1.000 0.816 0.740 0.790
HIV-SN, HIV sensory neuropathy; HIV–No SN, no HIV sensory neuropathy; QST, quantitative sensory testing criteria; CNE, clinical neurological examination; IENFD,
intraepidermal nerve ﬁbre density criteria.
a The case deﬁnition used in the study required the presence of 2 or more out of the following triumvirate: clinical signs of distal sensory neuropathy, 2 or more abnormal
QST parameters, or IENFD of 67.63 ﬁbres/mm (QST + CNE + IENFD). Each column shows the consequences of changing the case deﬁnition.
b Sensitivity and speciﬁcity compared to use of triumvirate of QST + CNE + IENFD criteria for diagnosis of HIV-SN.
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the diagnosis resulted in 8 (12.1%) participants having a different
diagnosis; not using IENFD results in a change in 6 (9.1%); and
removal of SNE resulted in the largest number of diagnosis
changes, at 17 (25.8)%.
The criteria most effective in isolation is SNE, with a sensitivity
and speciﬁcity of 1.00 and 0.740, followed by QST (sensitivity
0.786, speciﬁcity 0.816) and IENFD (sensitivity 0.607, speciﬁcity
0.790).
4. Discussion
In this ﬁrst report of the detailed HIV-SN phenotype in the cART
era, the predominant sensory feature was loss of function; 86% of
HIV-SN participants had loss of function in at least 1 sensory
modality. However, the degree to which individual modalities
were affected across the HIV-SN group did not correlate with either
symptoms (including pain) or neuropathy severity. No single sen-
sory parameter alone has diagnostic utility for HIV-SN.
The main sensory ﬁnding was loss of function of the Ab
ﬁbre-mediated sensory modalities of mechanical and vibration
detection thresholds. HIV-SN is usually described as a SFN; how-
ever, assessment of small ﬁbre function using thermal detection
thresholds did not detect abnormalities to a sufﬁcient extent to
yield diagnostically useful information, in contrast to the IENFD
measures. Similarly, no diagnostic utility was seen in heat supra-
threshold stimulus response testing. This is a similar ﬁnding to that
seen in a pre-cART-era study [8].
Although this was a small sample, 4 HIV-SN patients with pain
(14%) had increased WURs associated with raised catastrophizing
scores, of 26.0 (interquartile range 22.5–31.5) vs 12.0 (interquartile
range 0–22.0) (P < .05, Mann-Whitney rank sum test). Although
this sample is too small to draw conclusions, high WUR and raised
PCS have been related in phantom limb pain [65]. This merits fur-
ther study in a larger sample.
4.1. Intraepidermal nerve ﬁbre density
IENFD counts were lower in the HIV-SN group, and the severity
of neuropathy, using the TCSS, was inversely correlated to IENFD.
However, the diagnostic utility of counts <7.63 ﬁbres/mm can only
be considered moderate in isolation, with a sensitivity and speciﬁc-
ity of 61% and 79%, respectively, of detecting HIV-SN compared to
the study’s diagnostic triumvirate. Consistent with other reports,
no correlation was found between IENFD and sensory nerve ﬁbre
dysfunction for individual QST parameters [17], although contrast-
ing ﬁndings have been reported [59].
After recruitment had started, the guidelines for skin biopsy-
based diagnosis of small ﬁbre neuropathies were updated [36] to
recommend the use of sex/age-matched control data [3]. However,
the diagnostic utility of age/sex-matched normal values have been
compared [46]. Age/sex-adjusted cutoff values produced the bestspeciﬁcity (98%) but had low sensitivity (31%); a cutoff value of
10.3 ﬁbres/mm produced poorer speciﬁcity (64%) but improved
sensitivity (78%). The lower cutoff value of 7.63 ﬁbres/mm [20]
used in this study is associated with a speciﬁcity of 90% and sensi-
tivity of 80% and represents an appropriate compromise between
the age/sex-matched and ROC methods.
We used the per protocol criterion of 7.63 ﬁbres/mm as the cut-
off value in the triumvirate HIV-SN deﬁnition. Nevertheless, a post
hoc analysis using the 2010 guidelines was performed using the
recommended normative values. This analysis demonstrated no
change in HIV–No SN group allocation; however, 5 participants
(8%) originally allocated to HIV-SN were now allocated to HIV–
No SN. This was thought to be acceptable because the difference
is proportional to what would be expected using this more conser-
vative deﬁnition of HIV-SN. Additionally, 3 of the 5 participants
whose diagnoses were altered to HIV–No SN reported painful
peripheral neuropathy symptoms, suggesting that a diagnosis of
HIV-SN was likely to be correct for these participants.
4.2. Metabolic factors
Higher plasma TRG concentrations were measured in the HIV-
SN group compared to the HIV–No SN group. This ﬁnding under-
lines the emerging understanding that dyslipidaemia is important
in the development of HIV-SN [2,4] and other peripheral neuropa-
thies [66,71]. There was no difference in statin use between the 2
groups. The role of other metabolic factors in this study was less
clear.
4.3. Psychology, sleep dysfunction, and pain symptomatology
Participants with painful HIV-SN show interference from pain
on the BPI and reduced quality of life compared to participants
without neuropathy across most domains of the SF-36. Findings
were comparable to changes in quality of life in other painful
peripheral neuropathies, but HIV-SN appears to be associated with
greater disability [53] and poorer overall perception of general
health. Pain-related anxiety symptoms were similar to other pain
conditions across most domains [18] but with less report in HIV-
SN patients of escape/avoidance behavior.
Sleep laboratory and self-report insomnia data have been
reported in HIV infection [56]. However, few studies have examined
the role of pain or neuropathy in HIV-associated insomnia.We have
shown a higher incidence of insomnia in the painful HIV-SN group
compared to the HIV–No SN group. Other forms of neuropathic pain
are also associated with coincident insomnia [34].
The NPSI participants with painful HIV-SN reported experienc-
ing multiple neuropathic pain symptoms; however, burning, tin-
gling, pressure pain, and pressure-evoked pain were the most
frequently items to be reported as ‘moderate’ or ‘severe’. There
was no correlation between NPSI and QST parameters, which is
similar in other painful sensory neuropathies [24].
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The use of a robust composite HIV-SN deﬁnition as used herein
would prove time-consuming and expensive for use in most rou-
tine clinical practices. Part of the objectives of this study was to
investigate the utility of neuropathy screening tools that might
be useful in poor-resource settings.
The BPNS has been used as a screening tool in HIV-SN
[10,11,62,67]. We found both the TCSS and UENS to be superior
to the BPNS in the diagnosis of HIV-SN when using the triumvirate
diagnostic criterion as a comparator. However, unlike the BPNS or
TCSS, the UENS and triumvirate diagnostic criteria do not include a
symptom assessment, which perhaps explains why the UENS pro-
duced the most similar results to the triumvirate. The UENS has
been used in HIV-SN, and it correlated with measures of cutaneous
autonomic function and pain [6].
4.5. Epidemiological studies
The population recruited to this deep proﬁling study had a
prevalence of HIV-SN of 43%, with 75% of those reporting pain,
which is similar to larger epidemiological studies [12]. In the cART
era, HIV-SN prevalence is consistently reported at 40%
[22,49,62,67]. This supports the face validity of the triumvirate cri-
teria used, as it is likely that these ﬁndings would be applicable to
larger HIV populations and in different settings. However, this
study did not ﬁnd some of the well-established risk factors for
HIV-SN of height, age, and sex in the cART era to be important. This
study was powered as a deep phenotyping study and was not
designed to be large enough to elucidate these risk factors com-
pared to larger epidemiological studies [10,22,40,62,72].
A potential limitation of the study is that several items of the tri-
umvirate deﬁnition for HIV-SN are compared and contrasted
between the HIV–No SN group and HIV-SN group. It is clear from
our results thatno singleparameter alone shouldbeused in isolation
for the diagnosis at the level of the individual patient. There is thus
potential for a circular argument relating to the QST and IENFD ﬁnd-
ings. Therefore,weperformedan exercisewherewepost hoc altered
the case deﬁnition criteria to test whether these substantially chan-
ged the group allocations. Use of different combinations of the tri-
umvirate shows that the neuropathy diagnosis of individual
participants was not dramatically altered by removal of individual
items from the triumvirate. Removal of QST resulted in 8 (12%) of
the participants having an altered diagnosis, and IENFD only 6
(9%). Removal of SNE alters diagnosis in 17 (26%), demonstrating
that a careful structured clinical examination ismost critical inmak-
ing the diagnosis of HIV-SN. There is an argument that only loss of
function in the threshold QST parameters should be used in HIV-
SN diagnosis. The percentages of participants in the HIV-SN group
where such abnormal threshold values were present and used as
part of the case deﬁnition are as follows: CDT (21%), WDT (14%),
MDT (54%), VDT (50%), HPT (29%), and CPT (0%). When only loss-
of-threshold QSTmeasures in conjunctionwith the triumvirate def-
inition are used, only in 2 individuals (7% of HIV-SN group) was this
critical in the diagnosis, resulting in an altered group allocation from
HIV-SN to HIV–No SN, demonstrating that this did not substantially
change group allocations.
4.6. Summary
This study demonstrated that the most frequent changes seen
in QST are loss of function in the large ﬁbre parameters of mechan-
ical and vibration detection, despite HIV-SN often being described
as a SFN. The diagnostic limitation of QST, IENFD and clinical
examination in isolation has also been demonstrated. This study
has validated the use of UENS and TCSS in the diagnosis of HIV-SN,both of which were superior to the BPNS in the diagnosis of HIV-
SN. This study also supported the growing evidence that lipid
dyslipidaemia may play a role in the development of HIV-SN. Pain-
ful HIV-SN also appears to have a greater impact on quality of life
compared to other pain syndromes.
Future work should determine the triumvirate diagnostic crite-
ria’s validity and utility in other HIV populations. A detailed exami-
nation of the components of the triumvirate should also be
undertaken, as there is an urgent need to produce a simple and
robust diagnostic tool for large epidemiological studies in low-
resource environments and for use in future therapeutic efﬁcacy
trials.
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